Skip to content

Clinical Application Research Utilizing 3D Real Inversion Recovery (IR) MR Sequences in Meniere's Disease

Clinical Application Research Utilizing 3D Real Inversion Recovery (IR) MR Sequences in Meniere's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102489
Enrollment
Unknown
Registered
2025-05-15
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere's disease (MD)

Interventions

The Meniere Disease Group:NA

Sponsors

The first affiliated hostipal of nanchang university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnostic criteria: Meet the diagnostic criteria for Meniere's disease published by the American Academy of Otolaryngology Head and Neck Surgery (AO-HNS) in 2015, including typical episodes of vertigo (>=2, lasting 20 minutes to 12 hours), fluctuating hearing loss, tinnitus, or a feeling of stuffy ears. 2. Imaging examination: All patients were required to complete 3D-real IR sequence MRI examination 4 hours after intravenous injection of gadolinium contrast agent, and the image quality met the EH assessment requirements. 3. Clinical data integrity: Complete clinical data are available, including disease course (starting from the first diagnosis), symptom type (vertigo, tinnitus, ear tightness, hearing loss), pure tone hearing threshold measurement results (sub-low frequency, medium frequency, high frequency hearing loss), attack frequency (within the past 6 months), gender, age, etc.

Exclusion criteria

Exclusion criteria: 1. Other inner ear diseases (such as sudden deafness, vestibular neuritis, otosclerosis) Or central vertigo diseases (such as stroke, multiple sclerosis). History of ear surgery or trauma. 2. Gadolinium contrast allergy or MRI contraindications (e.g. metal implants, claustrophobia) Illness). 3. The clinical data is incomplete or the image quality does not meet the analysis requirements.

Design outcomes

Primary

MeasureTime frame
The presence and severity of endolymphatic hydrops (EH);The affected areas of endolymphatic hydrops (EH);

Secondary

MeasureTime frame
Disease course staging;Symptom type;Degree of hearing loss;Attack frequency;Demographic characteristics;

Countries

China

Contacts

Public ContactCheng Weiling

The first affiliated hostipal of nanchang university

ndyfy04042@ncu.edu.cn+86 13807916018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026